BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Vlachos C, Gaitanis G, Katsanos KH, Christodoulou DK, Tsianos E, Bassukas ID. Psoriasis and inflammatory bowel disease: links and risks. Psoriasis (Auckl) 2016;6:73-92. [PMID: 29387596 DOI: 10.2147/PTT.S85194] [Cited by in Crossref: 4] [Cited by in F6Publishing: 11] [Article Influence: 0.7] [Reference Citation Analysis]
Number Citing Articles
1 Ju J, Dai Y, Yang J, Liu C, Fan L, Feng L, Zhao B, Zeng M, Liu Z, Sun X. Crohn's disease exacerbated by IL-17 inhibitors in patients with psoriasis: a case report. BMC Gastroenterol 2020;20:340. [PMID: 33059618 DOI: 10.1186/s12876-020-01474-x] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
2 Liang X, Ou C, Zhuang J, Li J, Zhang F, Zhong Y, Chen Y. Interplay Between Skin Microbiota Dysbiosis and the Host Immune System in Psoriasis: Potential Pathogenesis. Front Immunol 2021;12:764384. [PMID: 34733291 DOI: 10.3389/fimmu.2021.764384] [Reference Citation Analysis]
3 Hung YT, Le PH, Kuo CJ, Tang YC, Chiou MJ, Chiu CT, Kuo CF, Huang YH. The Temporal Relationships and Associations between Cutaneous Manifestations and Inflammatory Bowel Disease: A Nationwide Population-Based Cohort Study. J Clin Med 2021;10:1311. [PMID: 33810197 DOI: 10.3390/jcm10061311] [Reference Citation Analysis]
4 De Pessemier B, Grine L, Debaere M, Maes A, Paetzold B, Callewaert C. Gut-Skin Axis: Current Knowledge of the Interrelationship between Microbial Dysbiosis and Skin Conditions. Microorganisms 2021;9:353. [PMID: 33670115 DOI: 10.3390/microorganisms9020353] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 9.0] [Reference Citation Analysis]
5 Sun C, Chen L, Yang H, Sun H, Xie Z, Zhao B, Jiang X, Qin B, Shen Z. Involvement of Gut Microbiota in the Development of Psoriasis Vulgaris. Front Nutr 2021;8:761978. [PMID: 34881280 DOI: 10.3389/fnut.2021.761978] [Reference Citation Analysis]
6 Schreiber S, Colombel JF, Feagan BG, Reich K, Deodhar AA, McInnes IB, Porter B, Das Gupta A, Pricop L, Fox T. Incidence rates of inflammatory bowel disease in patients with psoriasis, psoriatic arthritis and ankylosing spondylitis treated with secukinumab: a retrospective analysis of pooled data from 21 clinical trials. Ann Rheum Dis. 2019;78:473-479. [PMID: 30674475 DOI: 10.1136/annrheumdis-2018-214273] [Cited by in Crossref: 72] [Cited by in F6Publishing: 65] [Article Influence: 24.0] [Reference Citation Analysis]
7 Wawrzycki B, Pietrzak A, Grywalska E, Krasowska D, Chodorowska G, Roliński J. Interleukin-22 and Its Correlation with Disease Activity in Plaque Psoriasis. Arch Immunol Ther Exp (Warsz) 2019;67:103-8. [PMID: 30291393 DOI: 10.1007/s00005-018-0527-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
8 Napolitano M, Testa A, Ferrillo M, Villani A, Balato N, Megna M, Nardone OM, Fabbrocini G, Castiglione F. Psoriasis Features in Patients with Inflammatory Bowel Disease. Open Access Maced J Med Sci 2019;7:1001-3. [PMID: 30976349 DOI: 10.3889/oamjms.2019.161] [Reference Citation Analysis]
9 Jiang Y, Jarr K, Layton C, Gardner CD, Ashouri JF, Abreu MT, Sinha SR. Therapeutic Implications of Diet in Inflammatory Bowel Disease and Related Immune-Mediated Inflammatory Diseases. Nutrients 2021;13:890. [PMID: 33801883 DOI: 10.3390/nu13030890] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Veronese F, Graziola F, Cammarata E, Andreassi M, Mazzoletti V, Taglietti C, Navarra G, Savoia P, Tiberio R. The Diagnostic-Therapeutic Care Pathway in Psoriasis: Towards ISO 9001:2015 Certification. Medicina (Kaunas) 2020;56:E253. [PMID: 32455972 DOI: 10.3390/medicina56050253] [Reference Citation Analysis]
11 Vojdani A, Vojdani E, Herbert M, Kharrazian D. Correlation between Antibodies to Bacterial Lipopolysaccharides and Barrier Proteins in Sera Positive for ASCA and ANCA. Int J Mol Sci 2020;21:E1381. [PMID: 32085663 DOI: 10.3390/ijms21041381] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
12 Țiburcă L, Bembea M, Zaha DC, Jurca AD, Vesa CM, Rațiu IA, Jurca CM. The Treatment with Interleukin 17 Inhibitors and Immune-Mediated Inflammatory Diseases. CIMB 2022;44:1851-66. [DOI: 10.3390/cimb44050127] [Reference Citation Analysis]
13 Haidari W, Al-Naqshabandi S, Ahn CS, Bloomfeld RS, Feldman SR. Asymptomatic Crohn's disease identified in a patient being treated with secukinumab: A case report. SAGE Open Med Case Rep 2019;7:2050313X19893580. [PMID: 31839950 DOI: 10.1177/2050313X19893580] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
14 Pietrzak D, Pietrzak A, Krasowska D, Borzęcki A, Franciszkiewicz-Pietrzak K, Polkowska-Pruszyńska B, Baranowska M, Reich K. Digestive system in psoriasis: an update. Arch Dermatol Res 2017;309:679-93. [PMID: 28905102 DOI: 10.1007/s00403-017-1775-7] [Cited by in Crossref: 21] [Cited by in F6Publishing: 13] [Article Influence: 4.2] [Reference Citation Analysis]
15 Stehlikova Z, Kostovcikova K, Kverka M, Rossmann P, Dvorak J, Novosadova I, Kostovcik M, Coufal S, Srutkova D, Prochazkova P, Hudcovic T, Kozakova H, Stepankova R, Rob F, Juzlova K, Hercogova J, Tlaskalova-Hogenova H, Jiraskova Zakostelska Z. Crucial Role of Microbiota in Experimental Psoriasis Revealed by a Gnotobiotic Mouse Model. Front Microbiol 2019;10:236. [PMID: 30846974 DOI: 10.3389/fmicb.2019.00236] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
16 Dokoshi T, Seidman JS, Cavagnero KJ, Li F, Liggins MC, Taylor BC, Olvera J, Knight R, Chang JT, Salzman NH, Gallo RL. Skin inflammation activates intestinal stromal fibroblasts and promotes colitis. J Clin Invest 2021;131:e147614. [PMID: 34720087 DOI: 10.1172/JCI147614] [Reference Citation Analysis]